Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
By focusing on the middle 50% of the data, the IQR is resilient to outliers, in contrast to percentages, which can be skewed by outliers, potentially leading to misinterpretation
When patients decided to quit using GLP-1 medications, the results showed 92% of patients maintained at least 10% of weight loss
The predominant side effects include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal pain (affecting 10-50% of patients depending on the specific product and dose, particularly during dose escalation) Injection site reactions : redness, itching, or discomfort at the subcutaneous injection site Hypoglycaemia : particularly when combined with insulin or sulphonylureas Decreased appetite : an intended therapeutic effect that contributes to weight loss However, some patients do report changes in urinary frequency or patterns
It's a pay-per-order model with no subscription
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type
US$ 26.53
US$ 29.47
